Goldman Sachs Starts Talecris Biotherapeutics (TLCR) at Neutral
TLCR Hot Sheet
Rating Summary:1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Goldman Sachs initiates coverage on Talecris Biotherapeutics (Nasdaq: TLCR) with a Neutral rating and a 12-month price target of $24.
The firm said the market currently values the stock at trough earnings, as TLCR is in the early stages of what we believe will be a multi-year turnaround. Over the next several quarters, they expect TLCR to accelerate gross profit growth.
The firm said the market currently values the stock at trough earnings, as TLCR is in the early stages of what we believe will be a multi-year turnaround. Over the next several quarters, they expect TLCR to accelerate gross profit growth.
You May Also Be Interested In
- UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
- Barclays on U.S. REITs: Best Ideas List: Adding HPP; Removing ARE
- UPDATE: UBS Upgrades Assured Guaranty (AGO) to Buy; Opportunity Opens After Recent Dip on Moody's Review
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
